Semaglutide Alternatives: What Are Your Options for Weight Loss?

Written by Adam Maggio | Medically reviewed by Dr. James Whitfield, DO, FACOI

This article provides a comprehensive guide to Semaglutide Alternatives: What Are Your Options for Weight Loss?, covering essential aspects for practitioners and individuals. It delves into specific protocols and considerations for effective use.

The Rise of GLP-1 Agonists for Weight Loss

The landscape of weight management has been significantly transformed by the advent of glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda). These medications mimic the action of a natural gut hormone, GLP-1, which plays a crucial role in appetite regulation, glucose metabolism, and gastric emptying. While highly effective, leading to average weight losses of 10-17% of body weight, GLP-1 agonists are not suitable for everyone due to potential side effects, cost, or contraindications. For individuals seeking alternatives, a range of pharmacological and non-pharmacological options exist, each with its own mechanism of action, efficacy, and side effect profile. Understanding these alternatives is essential for personalized weight management strategies [1].

Pharmacological Alternatives to Semaglutide

Several other prescription medications are approved for chronic weight management, offering different approaches to appetite suppression and metabolic modulation:

• Liraglutide (Saxenda): Another GLP-1 receptor agonist, administered daily via injection. It also promotes satiety and reduces food intake, with an average weight loss of 5-10%. Side effects are similar to semaglutide, primarily gastrointestinal.
• Tirzepatide (Zepbound, Mounjaro): A novel dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist. It offers even greater weight loss efficacy than semaglutide, with average reductions of 15-22% in clinical trials. It is administered weekly via injection. Side effects are similar to other GLP-1 agonists.
• Phentermine/Topiramate (Qsymia): A combination medication that suppresses appetite and increases satiety. Phentermine is a stimulant, and topiramate is an anticonvulsant. Average weight loss is typically 7-10%. Potential side effects include dry mouth, constipation, paresthesia, and increased heart rate. It is contraindicated in patients with glaucoma or hyperthyroidism.
• Naltrexone/Bupropion (Contrave): This combination targets reward pathways in the brain to reduce cravings and appetite. Bupropion is an antidepressant, and naltrexone is an opioid antagonist. Average weight loss is around 5%. Side effects can include nausea, constipation, headache, and dizziness. It carries a black box warning for suicidal thoughts and behaviors.
• Orlistat (Xenical, Alli): A lipase inhibitor that reduces the absorption of dietary fat by about 30%. It is available both by prescription (Xenical) and over-the-counter (Alli). Average weight loss is modest, typically 2-3%. Common side effects include steatorrhea, fecal urgency, and oily spotting, which can be mitigated by reducing dietary fat intake.

The choice of medication depends on individual patient characteristics, comorbidities, contraindications, and tolerance to side effects. A thorough discussion with a healthcare provider is essential to determine the most appropriate option [2].

Non-Pharmacological and Lifestyle Interventions

For individuals who prefer or require non-pharmacological approaches, comprehensive lifestyle interventions remain the cornerstone of weight management:

• Dietary Modifications: Adopting a balanced, calorie-controlled diet rich in whole foods, lean proteins, fruits, and vegetables is fundamental. Various dietary patterns, such as Mediterranean, low-carbohydrate, or plant-based diets, can be effective when adhered to consistently.
• Increased Physical Activity: Regular exercise, combining aerobic activity (e.g., 150-300 minutes of moderate-intensity activity per week) and strength training, is crucial for increasing energy expenditure, preserving muscle mass, and improving metabolic health.
• Behavioral Therapy: Working with a registered dietitian or a behavioral therapist can help identify and modify eating behaviors, address emotional eating, and develop sustainable habits.
• Bariatric Surgery: For individuals with severe obesity (BMI >40 kg/m² or >35 kg/m² with comorbidities), bariatric surgery (e.g., gastric bypass, sleeve gastrectomy) offers the most significant and durable weight loss, often 25-35% of total body weight. It also leads to substantial improvements in obesity-related comorbidities.

Combining lifestyle interventions with pharmacological treatments often yields the best results. The decision to use any weight loss intervention should be made in consultation with a healthcare professional, considering individual health status, goals, and potential risks and benefits [3].

References

• [1] Rubino, D. M., et al. (2021). Effect of Weekly Subcutaneous Semaglutide vs Placebo on Sustained Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta-analysis. JAMA, 325(14), 1414-1425.
• [2] Khera, R., et al. (2016). Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA, 315(22), 2424-2434.
• [3] Jensen, M. D., et al. (2014). 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Obesity Society. Circulation, 129(25 Suppl 2), S102-S138.